$14.99
-0.58[-3.73%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
Get Real Time Here
$14.99
0[0.00%]
| Open15.740 | Close14.910 |
| Vol / Avg.2.857M / 2.372M | Mkt Cap1.689B |
| Day Range14.880 - 15.910 | 52 Wk Range3.155 - 18.200 |
CymaBay Therapeutics Stock (NASDAQ:CBAY), Key Statistics
CymaBay Therapeutics Stock (NASDAQ: CBAY) analysis, key statistics.
Valuation Measures
Enterprise Value
1.6B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
47.16
Price / Book (mrq)
16.18
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-5.72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.96
Tangible Book value per share
0.96
Total Liabilities (Quarterly)
118.2M
Total Assets
226.7M
Total Liabilities
118.2M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-2.61%
EBIT Margin
12.28%
EBITDA Margin
12.96%
Operating Margin
-0.32%
CymaBay Therapeutics Stock (NASDAQ:CBAY), Key Statistics
CymaBay Therapeutics Stock (NASDAQ: CBAY) analysis, key statistics.
Valuation Measures
Enterprise Value
1.6B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
47.16
Price / Book (mrq)
16.18
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-5.72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.96
Tangible Book value per share
0.96
Total Liabilities (Quarterly)
118.2M
Total Assets
226.7M
Total Liabilities
118.2M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-2.61%
EBIT Margin
12.28%
EBITDA Margin
12.96%
Operating Margin
-0.32%
CymaBay Therapeutics Stock (NASDAQ:CBAY), Key Statistics
CymaBay Therapeutics Stock (NASDAQ: CBAY) analysis, key statistics.
Valuation Measures
Enterprise Value
1.6B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
47.16
Price / Book (mrq)
16.18
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-5.72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.96
Tangible Book value per share
0.96
Total Liabilities (Quarterly)
118.2M
Total Assets
226.7M
Total Liabilities
118.2M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-2.61%
EBIT Margin
12.28%
EBITDA Margin
12.96%
Operating Margin
-0.32%
CymaBay Therapeutics Stock (NASDAQ:CBAY), Key Statistics
CymaBay Therapeutics Stock (NASDAQ: CBAY) analysis, key statistics.
Valuation Measures
Enterprise Value
1.6B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
47.16
Price / Book (mrq)
16.18
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-5.72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.96
Tangible Book value per share
0.96
Total Liabilities (Quarterly)
118.2M
Total Assets
226.7M
Total Liabilities
118.2M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-2.61%
EBIT Margin
12.28%
EBITDA Margin
12.96%
Operating Margin
-0.32%
CymaBay Therapeutics Stock (NASDAQ:CBAY), Key Statistics
CymaBay Therapeutics Stock (NASDAQ: CBAY) analysis, key statistics.
Valuation Measures
Enterprise Value
1.6B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
47.16
Price / Book (mrq)
16.18
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-5.72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.96
Tangible Book value per share
0.96
Total Liabilities (Quarterly)
118.2M
Total Assets
226.7M
Total Liabilities
118.2M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-2.61%
EBIT Margin
12.28%
EBITDA Margin
12.96%
Operating Margin
-0.32%
CymaBay Therapeutics Stock (NASDAQ:CBAY), Key Statistics
CymaBay Therapeutics Stock (NASDAQ: CBAY) analysis, key statistics.
Valuation Measures
Enterprise Value
1.6B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
47.16
Price / Book (mrq)
16.18
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-5.72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.96
Tangible Book value per share
0.96
Total Liabilities (Quarterly)
118.2M
Total Assets
226.7M
Total Liabilities
118.2M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-2.61%
EBIT Margin
12.28%
EBITDA Margin
12.96%
Operating Margin
-0.32%
CymaBay Therapeutics Stock (NASDAQ:CBAY), Key Statistics
CymaBay Therapeutics Stock (NASDAQ: CBAY) analysis, key statistics.
Valuation Measures
Enterprise Value
1.6B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
47.16
Price / Book (mrq)
16.18
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-5.72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.96
Tangible Book value per share
0.96
Total Liabilities (Quarterly)
118.2M
Total Assets
226.7M
Total Liabilities
118.2M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-2.61%
EBIT Margin
12.28%
EBITDA Margin
12.96%
Operating Margin
-0.32%
CymaBay Therapeutics Stock (NASDAQ:CBAY), Key Statistics
CymaBay Therapeutics Stock (NASDAQ: CBAY) analysis, key statistics.
Valuation Measures
Enterprise Value
1.6B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
47.16
Price / Book (mrq)
16.18
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-5.72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.96
Tangible Book value per share
0.96
Total Liabilities (Quarterly)
118.2M
Total Assets
226.7M
Total Liabilities
118.2M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-2.61%
EBIT Margin
12.28%
EBITDA Margin
12.96%
Operating Margin
-0.32%
CymaBay Therapeutics Stock (NASDAQ:CBAY), Key Statistics
CymaBay Therapeutics Stock (NASDAQ: CBAY) analysis, key statistics.
Valuation Measures
Enterprise Value
1.6B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
47.16
Price / Book (mrq)
16.18
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-5.72%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
0.96
Tangible Book value per share
0.96
Total Liabilities (Quarterly)
118.2M
Total Assets
226.7M
Total Liabilities
118.2M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-2.61%
EBIT Margin
12.28%
EBITDA Margin
12.96%
Operating Margin
-0.32%